BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 24254749)

  • 1. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
    Boye K; Del Prever AB; Eriksson M; Saeter G; Tienghi A; Lindholm P; Fagioli F; Skjeldal S; Ferrari S; Hall KS
    Pediatr Blood Cancer; 2014 May; 61(5):840-5. PubMed ID: 24254749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
    Lashkari A; Chow WA; Valdes F; Leong L; Phan V; Twardowski P; Kapoor N; Molina A; Al-Kadhimi Z; Frankel P; Somlo G
    Anticancer Res; 2009 Aug; 29(8):3281-8. PubMed ID: 19661346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic osteosarcoma.
    Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
    Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
    Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
    Harris MB; Gieser P; Goorin AM; Ayala A; Shochat SJ; Ferguson WS; Holbrook T; Link MP
    J Clin Oncol; 1998 Nov; 16(11):3641-8. PubMed ID: 9817286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
    Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
    J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
    Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
    Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
    Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
    Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
    Piperno-Neumann S; Ray-Coquard I; Occean BV; Laurence V; Cupissol D; Perrin C; Penel N; Bompas E; Rios M; Le Cesne A; Italiano A; Anract P; de Pinieux G; Collard O; Bertucci F; Duffaud F; Le Deley MC; Delaye J; Brugieres L; Blay JY
    Int J Cancer; 2020 Jan; 146(2):413-423. PubMed ID: 31246277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
    Banna GL; De Giorgi U; Ferrari B; Castagna L; Alloisio M; Marangolo M; Rosti G; Santoro A
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1085-91. PubMed ID: 17084372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933.
    MacDonald TJ; Arenson EB; Ater J; Sposto R; Bevan HE; Bruner J; Deutsch M; Kurczynski E; Luerssen T; McGuire-Cullen P; O'Brien R; Shah N; Steinbok P; Strain J; Thomson J; Holmes E; Vezina G; Yates A; Phillips P; Packer R
    Cancer; 2005 Dec; 104(12):2862-71. PubMed ID: 16315242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
    McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
    Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
    Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
    Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.